- Home
- ONCY vs ATOS Comparison
ONCY vs ATOS Comparison
Compare ONCY & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- ATOS
- Stock Information
- Founded
- ONCY 1998
- ATOS 2009
- Country
- ONCY Canada
- ATOS United States
- Employees
- ONCY N/A
- ATOS N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- ATOS Health Care
- Exchange
- ONCY Nasdaq
- ATOS Nasdaq
- Market Cap
- ONCY 106.1M
- ATOS 100.8M
- IPO Year
- ONCY 1999
- ATOS 2012
- Fundamental
- Price
- ONCY $0.99
- ATOS $0.78
- Analyst Decision
- ONCY Strong Buy
- ATOS Strong Buy
- Analyst Count
- ONCY 6
- ATOS 3
- Target Price
- ONCY $6.00
- ATOS $6.25
- AVG Volume (30 Days)
- ONCY 750.7K
- ATOS 535.2K
- Earning Date
- ONCY 11-12-2025
- ATOS 11-12-2025
- Dividend Yield
- ONCY N/A
- ATOS N/A
- EPS Growth
- ONCY N/A
- ATOS N/A
- EPS
- ONCY N/A
- ATOS N/A
- Revenue
- ONCY N/A
- ATOS N/A
- Revenue This Year
- ONCY N/A
- ATOS N/A
- Revenue Next Year
- ONCY N/A
- ATOS N/A
- P/E Ratio
- ONCY N/A
- ATOS N/A
- Revenue Growth
- ONCY N/A
- ATOS N/A
- 52 Week Low
- ONCY $0.33
- ATOS $0.55
- 52 Week High
- ONCY $1.51
- ATOS $1.32
- Technical
- Relative Strength Index (RSI)
- ONCY 39.40
- ATOS 39.37
- Support Level
- ONCY $0.97
- ATOS $0.74
- Resistance Level
- ONCY $1.05
- ATOS $0.81
- Average True Range (ATR)
- ONCY 0.06
- ATOS 0.05
- MACD
- ONCY 0.00
- ATOS 0.00
- Stochastic Oscillator
- ONCY 42.83
- ATOS 26.30
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.